Plasma Clot Lysis Time and Its Association with Cardiovascular Risk Factors in Black Africans

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  de Lange, Zelda ^a   Pieters, Marlien ^a   Jerling, Johann C ^a   Kruger, Annamarie ^a   Rijken, Dingeman C ^b  

^a NORTH WEST UNIVERSITY   (South Africa)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; HEMOGLOBIN A1C; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; AFRICA; ALCOHOL CONSUMPTION; ARTICLE; BLOOD CLOT LYSIS; BODY MASS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NEGRO; RISK ASSESSMENT; RURAL POPULATION; SEX DIFFERENCE; SMOKING; URBAN POPULATION; URBANIZATION;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ALCOHOL DRINKING; CARDIOVASCULAR DISEASES; FEMALE; FIBRIN CLOT LYSIS TIME; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; POPULATION DYNAMICS; RISK FACTORS; RURAL POPULATION; URBANIZATION;

EID: 84869051730     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048881     Document Type: Article

References (30)

1. Yusuf S, Reddy S, Ounpuu S, Anand S, (2001) Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 104: 2855-2864.
2. Collen D, Lijnen HR, (1991) Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78: 3114-3124.
3. Gorog DA, (2010) Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease. J Am Coll Cardiol 55: 2701-2709.
4. Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, et al. (2001) Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 121: 131-139.
5. Lisman T, De Groot PG, Meijers J, Rosendaal FR, (2005) Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 105: 1102-1105.
6. Meltzer ME, Lisman T, Doggen CJ, De Groot PG, Rosendaal FR, (2008) Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS Med 5: 751-759.
7. Guimarães AHC, De Bruijne ELE, Lisman T, Dippel DWJ, Deckers JW, et al. (2009) Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br J Haematol 145: 115-120.
8. Meltzer ME, Doggen CJM, De Groot PG, Rosendaal FR, Lisman T, (2009) Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men. Br J Haematol 145: 121-127.
9. Leander K, Blombäck M, Wallén H, He S, (2012) Impaired fibrinolytic capacity and increased fibrin formation associate with myocardial infarction. Thromb Haemost 107: 1092-1099.
10. Siegerink B, Meltzer ME, de Groot PG, Algra A, Lisman T, et al. (2011) Clot lysis time and the risk of myocardial infarction and ischaemic stroke in young women; results from the RATIO case-control study. Br J Haematol 156: 252-258.
11. Steyn K, Sliwa K, Hawken S, Commerford P, Onen C, et al. (2005) Risk factors associated with myocardial infarction in Africa. Circulation 112: 3554-3561.
12. Pieters M, Dolman R, Ntyintyane L, Jerling J, Raal F, (2011) Risk factor profile of coronary artery disease in black South Africans. S Afr Heart J 8: 4-11.
13. Fuster V, Kelly BB (2010) Promoting cardiovascular health in the developing world: A critical challenge to achieve global health. Washington D.C: The National Academies Press. 484 p.
14. Vorster H, (2002) The emergence of cardiovascular disease during urbanisation of Africans. Public Health Nutr 5: 239-243.
15. Pieters M, de Maat MPM, Jerling JC, Hoekstra T, Kruger A, (2011) Fibrinogen concentration and its role in CVD risk in black South Africans-effect of urbanisation. Thromb Haemost 106: 448-456.
16. Teo K, Chow CK, Vaz M, Rangarajan S, Yusuf S, (2009) The Prospective Urban Rural Epidemiology (PURE) study: Examining the impact of societal influences on chronic non-communicable diseases in low-, middle-, and high-income countries. Am Heart J 158: 1-7.
17. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, et al. (2011) Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 378: 1231-1243.
18. Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2009) Harmonizing the metabolic syndrome. Circulation 120: 1640-1645.
19. Meltzer ME, Lisman T, de Groot PG, Meijers JCM, le Cessie S, et al. (2010) Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 116: 112-121.
20. Pieters M, de Lange Z, Hoekstra T, Ellis SM, Kruger A, (2010) Triglyceride concentration and waist circumference influence alcohol-related plasminogen activator inhibitor-1 activity increase in black South Africans. Blood Coagul Fibrinolysis 21: 736-743.
21. Alessi M, Peiretti F, Morange P, Henry M, Nalbone G, et al. (1997) Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46: 860-867.
22. Bastelica D, Morange P, Berthet B, Borghi H, Lacroix O, et al. (2002) Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: Evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 22: 173-178.
23. Alessi MC, Bastelica D, Morange P, Berthet B, Leduc I, et al. (2000) Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 49: 1374-1380.
24. Samad F, Yamamoto K, Loskutoff DJ, (1996) Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 97: 37-46.
25. Carter AM, Cymbalista CM, Spector TD, Grant PJ, (2007) Heritability of clot formation, morphology, and lysis. Arterioscler Thromb Vasc Biol 27: 2783-2789.
26. Kim PY, Stewart RJ, Lipson SM, Nesheim ME, (2007) The relative kinetics of clotting and lysis provide a biochemical rationale for the correlation between elevated fibrinogen and cardiovascular disease. J Thromb Haemost 5: 1250-1256.
27. Falls LA, Farrell DH, (1997) Resistance of gammaA/gamma' fibrin clots to fibrinolysis. J Biol Chem 272: 14251-14256.
28. Ryan EA, Mockros LF, Weisel JW, Lorand L, (1999) Structural origins of fibrin clot rheology. Biophys J 77: 2813-2826.
29. Hadigan C, Meigs J, Rabe J, D'agostino R, Wilson P, et al. (2001) Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 86: 939-943.
30. Fourie C, Van Rooyen J, Pieters M, Conradie K, Hoekstra T, et al. (2011) Is HIV-1 infection associated with endothelial dysfunction in a population of African ancestry in South Africa? Cardiovasc J Africa 22: 134-140.